Classes: Mides, Mibs, MAbs and Others to Treat Myeloma
Myeloma Drug Timeline
Guide to Drug Names
| GENERIC NAME | BRAND NAME | ORIGINAL NAME |
|---|---|---|
|
afuresertib |
GSK2110183 |
|
|
bendamustine |
Treanda® |
SDX-105 |
| bortezomib |
Velcade® |
PS-341 |
|
carfilzomib |
Kyprolis® |
PR-171 |
|
cyclophosphamide |
Cytoxan® |
|
|
dabrafenib |
Tafinlar® |
|
|
daratumumab |
Darzalex® |
CD38 mAb |
|
dasatinib |
Sprycel® |
BMS-354825 |
|
denosumab |
XGEVA® |
AMG-162, osteoprotegerin |
|
dinaciclib |
SCH 727965 |
|
|
durvalumab |
MED14736 |
|
|
eltrombopag |
Promacta® |
|
|
elotuzumab |
Empliciti® |
HuLuc63 |
|
everolimus |
Afinitor® |
LY317615 |
|
filanesib |
ARRY-520 |
|
|
Ibrutinib |
Imbruvica® |
PCI-32765 |
|
indatuximab ravtansine |
|
BT062 |
|
ipilumumab |
Yervoy® |
|
|
ixazomib |
Ninlaro® |
MLN9708 |
|
lenalidomide |
Revlimid® |
CC-5013 |
|
lirilumab |
|
IPH-2102, BMS-986015 |
|
marizomib |
|
NPI-0052, salinosporamide |
|
masitinib |
|
AB1010 |
|
melphalan |
Alkeran® |
|
|
nelfinavir |
Viracept® |
|
|
nivolumab |
Opdivo® |
BMS-936558 |
|
oprozomib |
|
ONX-0912 |
|
palbociclib |
Ibrance® |
PD 0332991 |
|
pamidronate |
Aredia® |
|
|
panobinostat |
Farydak® |
LBH589 |
|
pegylated liposomal doxorubicin |
Doxil® |
|
|
pembrolizumab |
Keytruda® |
MK-3475-013 |
|
pidilizumab |
|
CT-011 |
|
plerixafor |
Mozobil® |
AMD3100 |
|
plitidepsin |
Aplidin® |
|
|
pomalidomide |
Pomalyst® |
CC-4047 |
|
quisinostat |
|
JNJ26481585 |
|
ricolinostat |
|
ACY-1215 |
|
romidepsin |
Istodax® |
FK228, depsipeptide |
|
selinexor |
|
KPT-330 |
|
sirolimus |
Rapamune® |
rapamycin, AY 22989 |
|
sonidegib |
Odomzo® |
LDE225, erismodegib |
|
sotatercept |
|
ACE-011 |
|
temsirolimus |
Torisel® |
CCI-779 |
|
thalidomide |
Thalomid® |
|
|
trametinib |
Mekinist® |
GSK11202 |
|
ulocuplumab |
|
BMS-936564 |
|
urelumab |
|
BMS-663513 |
|
venetoclax |
Venclexta® |
ABT-199 |
|
vorinostat |
Zolinza® |
SAHA |
|
zoledronic acid, zoledronate |
Zometa® |
|
